Embedded Files
PharmedOut sends letter to FDA on vaginal estrogens
2023
2023
- Why are opioids approved for chronic pain when they don’t work? By Judy Butler, Research Fellow (May 2023)
2021
2021
The House and the Senate Take on Opioid Marketing By Judy Butler, Research Fellow (January 2021)
Why is the AMA Promoting Opioid Use? By Judy Butler, Research Fellow (February 2021)
Opioid Marketing Tactics: The Old and the New By Judy Butler, Research Fellow (March 2021)
New and Convenient Does Not Equal Better and Safe By Judy Butler, Research Fellow (April 2021)
Manufacturing Doubt and Evading Responsibility By Judy Butler, Research Fellow (September 2021)
The FDA Should Mandate Industry-free CME by Judy Butler, Research Fellow (October 2021)
Sales of Some Opioids Lift Sales of All Opioids by Judy Butler, Research Fellow (November 2021)
2020
2020
Story vs. Anti-Story in Opioid Marketing By Judy Butler, Research Fellow (January 2020)
The Trouble with Tramadol By Judy Butler, Research Fellow (February 2020)
Triplicate States and Opioid Prescribing By Judy Butler, Research Fellow (May 2020)
Industry's Influence on Pain Patients' Advocacy By Judy Butler, Research Fellow (October 2020)
McKinsey Proposed What to Purdue? By Judy Butler, Research Fellow (December 2020)
2019
2019
What Really Helps Chronic Pain Patients By Judy Butler, Research Fellow (February 2019)
Industry's Voice, Pain Patient's Face By Judy Butler, Research Fellow (March 2019)
Who's Really Advocating for Pain Patients By Judy Butler, Research Fellow (April 2019)
Preventing a new generation of opioid “legacy patients" By Judy Butler, Research Fellow (May 2019)
When Sunshine Doesn't Cast Enough Light By Judy Butler, Research Fellow (November 2019)
2018
2018
Purdue's Latest PR Move By Judy Butler, Research Fellow (April 2018)
Subsys Sales, from Salacious to Scammy By Judy Butler, Research Fellow (July 2018)
A Million Ways to Market A Pill By Judy Butler, Research Fellow (August 2018)
Make Punishment Personal By Judy Butler, Research Fellow (November 2018)
An opioid treatment for depression nixed by FDA advisory committee By Ben Goodwin (December 2018)
Report abuse